FDA 483 - Noble Life Sciences, Inc - June 20, 2025

An FDA inspection of Noble Life Sciences, Inc., a nonclinical laboratory in Sykesville, MD, revealed significant deficiencies in facility maintenance, equipment sanitation, and quality assurance practices. Observations included pest harborage, unclean animal housing and equipment, and multiple deviations from approved protocols and standard operating procedures. These issues indicate a lack of adequate control over the testing environment and processes.